Wire · operational-macro
Dispatches from CGT International: Big pharma M&A is the new biotech IPO
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 September 2026 · Fusion42 review
The biotech IPO market has slowed significantly, with big pharmaceutical companies increasingly acquiring biotech firms as an alternative exit strategy. Eli Lilly's recent acquisition spree in cell and gene therapy highlights a shift where pharma companies provide commercial expertise while relying on biotech innovation.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Big pharma's pivot to buying biotech companies rather than relying on IPOs opens immediate deal opportunities and reshapes exit strategies for biotech founders. You must now consider pharma acquisition terms as your primary path to scale and should position accordingly for those buyers.
◆ Coverage
1 source · 25 Sep 2026
◆ Related on Wire
◆ Topics